GlobeImmune, Inc., today announced that on February 11, 2014, the company completed a $7.5 million private placement of convertible notes and warrants. Continue reading
GlobeImmune presents GI-4000 Phase 2 NSCLC data at IASLC Continue reading
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) Continue reading
LOUISVILLE, Colo., September 4, 2013 – GlobeImmune, Inc., announced today that it has been awarded a $4 million Research Project Grant (R01) by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to … Continue reading
GlobeImmune, Inc., today announced that Timothy C. Rodell, M.D. will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 in New York. Continue reading
GlobeImmune, Inc., announced today the initiation of a Phase 2 clinical trial at the National Cancer Institute (NCI) to evaluate GI-6207 in subjects with medullary thyroid cancer (MTC). Continue reading
LOUISVILLE, Colo., Jan. 28, 2013 – GlobeImmune, Inc., today announced the initiation of a Phase 1a clinical trial to investigate the safety and immunogenicity of GI-13020 in healthy volunteers. The GI-13020 Tarmogen®, which GlobeImmune is developing in collaboration with Gilead … Continue reading
Clinical Trial Data to be Presented at The Liver Meeting® 2012 in Boston BOSTON, Nov. 11, 2012 – GlobeImmune, Inc., today announced Phase 2b clinical data showing that GI-5005, a Tarmogen® product candidate for the treatment of chronic hepatitis C … Continue reading
Data to be Presented Today at The Liver Meeting® 2012 in Boston BOSTON, Nov. 10, 2012 – GlobeImmune, Inc. today announced that GI-13020, an investigational therapeutic vaccine designed using the company’s proprietary Tarmogen® product platform for the treatment of chronic … Continue reading
LOUISVILLE, Colo., July 2, 2012 – GlobeImmune, Inc., today announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. GlobeImmune … Continue reading